Evidence map›Paper›PMID 32714920›Full record

ArticleFrontiers in bioengineering and biotechnology2020

VEGF Over-Expression by Engineered BMSC Accelerates Functional Perfusion, Improving Tissue Density and In-Growth in Clinical-Size Osteogenic Grafts.

Rene' D Largo, Maximilian G Burger, Oliver Harschnitz, Conny F Waschkies, Andrea Grosso, Celeste Scotti, Alexandre Kaempfen, Sinan Gueven, Gernot Jundt, Arnaud Scherberich and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Rene' D LargoCell and Gene Therapy, Department of Biomedicine, >Basel University Hospital and University of Basel, Basel, Switzerland.
Maximilian G BurgerCell and Gene Therapy, Department of Biomedicine, >Basel University Hospital and University of Basel, Basel, Switzerland.
Oliver HarschnitzCell and Gene Therapy, Department of Biomedicine, >Basel University Hospital and University of Basel, Basel, Switzerland.
Conny F WaschkiesInstitute for Biomedical Engineering, ETH and University of Zurich, Zurich, Switzerland.
Andrea GrossoCell and Gene Therapy, Department of Biomedicine, >Basel University Hospital and University of Basel, Basel, Switzerland.
Celeste ScottiTissue Engineering, Department of Biomedicine, University Hospital of Basel, University of Basel, Basel, Switzerland.
Alexandre KaempfenPlastic and Reconstructive Surgery, Department of Surgery, Basel University Hospital and University of Basel, Basel, Switzerland.
Sinan GuevenTissue Engineering, Department of Biomedicine, University Hospital of Basel, University of Basel, Basel, Switzerland.
Gernot JundtInstitute of Pathology, University Hospital of Basel, Basel, Switzerland.
Arnaud ScherberichTissue Engineering, Department of Biomedicine, University Hospital of Basel, University of Basel, Basel, Switzerland.
Dirk J SchaeferPlastic and Reconstructive Surgery, Department of Surgery, Basel University Hospital and University of Basel, Basel, Switzerland.
Andrea BanfiCell and Gene Therapy, Department of Biomedicine, >Basel University Hospital and University of Basel, Basel, Switzerland.
Nunzia Di MaggioCell and Gene Therapy, Department of Biomedicine, >Basel University Hospital and University of Basel, Basel, Switzerland.
University Hospital of Basel · CHUniversity of Basel · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first choice for reconstruction of clinical-size bone defects consists of autologous bone flaps, which often lack the required mechanical strength and cause significant donor-site morbidity. We have previously developed biological substitutes in a rabbit model by combining bone tissue engineering and flap pre-fabrication. However, spontaneous vascularization was insufficient to ensure progenitor survival in the core of the constructs. Here, we hypothesized that increased angiogenic stimulation within constructs by exogenous VEGF can significantly accelerate early vascularization and tissue in-growth. Bone marrow stromal cells from NZW rabbits (rBMSC) were transduced with a retroviral vector to express rabbit VEGF linked to a truncated version of rabbit CD4 as a cell-surface marker. Autologous cells were seeded in clinical-size 5.5 cm

Indexed as

bone marrow stromal cellsgene therapyosteogenic graftsvascularizationVEGF

Identifiers

PMID32714920
PMCPMC7351518
OpenAlexW3038979138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.